Patent portfolios protecting 10 top selling prescription drugs

13 May 2024 - In this cross-sectional study of 1429 patents and patent applications protecting the 10 highest revenue brand name ...

Read more →

Biologic patent thickets and terminal disclaimers

14 December 2023 - Spending on biologics in 2021 represented $260 billion or 46% of all spending on prescription drugs in ...

Read more →

Biden Administration could seize patents for high priced drugs

7 December 2023 - The Biden administration proposed a rule Thursday that could let the Government seize patents for medicines developed ...

Read more →

Inequitable conduct and invalidation of patents related to FDA regulated products

13 November 2023 - Median brand name drug launch prices increased from $2,115 in 2008 to $180,007 in 2021. ...

Read more →

Ancillary product patents to extend biologic patent life

13 November 2023 - In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic ...

Read more →

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

2 October 2023 - A US Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo ...

Read more →

Changes in the number of continuation patents on drugs approved by the FDA

1 August 2023 - Brand name pharmaceutical manufacturers often sustain high prices in the US by obtaining patents that delay generic ...

Read more →

Commonwealth loses appeal in clopidogrel PBS damages undertaking case: important lessons for patentees and generics alike

27 June 2023 - Commonwealth claims on the damages undertaking remain a live issue for patentees and generics to consider. ...

Read more →

Patent system key to lower drug prices, experts say

9 March 2023 - Following the Biden administration’s progress towards lowering prescription drug prices with Medicare price negotiations, some industry ...

Read more →

How a drug company made $114 billion by gaming the US patent system

28 January 2023 - AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. ...

Read more →

Patent reform and lower drug prices should be bipartisan priorities

25 January 2023 - As the 118th Congress convenes this month in Washington D.C., many pundits and advocates have little ...

Read more →

Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following a favourable Canadian Federal Court of Appeal ruling

17 January 2023 - Medunik Canada is pleased to announce that on 9 January 2023, the Federal Court of Appeal of ...

Read more →

Recent patent reform bills and their implications for prescription drugs

13 January 2022 - In 2022, several bills were introduced in Congress to revamp US intellectual property law.  ...

Read more →

US backs delay to decision on COVID patent waiver extension

6 December 2022 - The United States on Tuesday urged delaying a decision on whether to waive patent protection for ...

Read more →

US Supreme Court to hear Amgen bid to revive cholesterol drug patents

4 November 2022 - The US Supreme Court on Friday agreed to hear Amgen's bid to revive patents on its ...

Read more →